EL7.AI
StocksMedium•18 November 2026•
3 min read

Novartis wins FDA approval for 150 mg Cosentyx to treat polymyalgia rheumatica

Key Facts

1The FDA approved Cosentyx at a dose of 150 mg to treat adults who do not respond adequately to corticosteroids or cannot tolerate dose reductions.
2Novartis estimated that about 966,000 people in the United States have polymyalgia rheumatica and said relapses may affect up to 40% during the first year.
3Cosentyx sales totaled $1.857 billion in the third quarter of 2026, up 9% year over year at constant currencies.
4The European Commission approved Cosentyx to treat the disease on October 21, 2026.

Novartis said the U.S. Food and Drug Administration approved Cosentyx, or secukinumab, at a dose of 150 mg to treat adults with polymyalgia rheumatica. The approval covers patients who do not respond adequately to corticosteroids or cannot tolerate dose reductions, according to the company’s statement. The decision adds the drug to the approved options for a group of patients whose treatment becomes difficult when reducing reliance on these medicines. Novartis said Cosentyx is the first anti-interleukin-17 biologic approved to treat the disease. The description is based on the drug’s mechanism and therapeutic class, according to the company’s statement.

Novartis said the phase 3 REPLENISH trial met all primary and secondary endpoints among participants who received doses of 300 and 150 mg. The company added that the trial found no new safety signals in the patients with polymyalgia rheumatica who took part. It said the results showed a higher proportion of patients achieved sustained remission with Cosentyx. The trial’s global lead investigator said the results “support IL-17A inhibition as a promising treatment approach.” These results provide a clinical basis for the approval, while the information provided here does not include detailed remission rates or other numerical measures comparing treatment groups.

Cosentyx treats a disease that Novartis said affects about 966,000 people in the United States. According to the company’s estimate, relapses may affect up to 40% of patients during the first year. The rate highlights the importance of sustained remission for patients, an outcome the company said the REPLENISH trial showed had improved with the drug. The company had previously said the published trial results support reducing cumulative steroid doses. These data place the drug’s use in the context of a disease in which relapses may recur, while the need remains to balance disease control with reduced exposure to steroid treatment.

The FDA approval followed the European Commission’s approval of Cosentyx for adults with the disease on October 21, 2026. The European approval covered patients who had not responded adequately to glucocorticoids or had relapsed when their doses were reduced, according to Novartis. The company said in June 2026 that REPLENISH data had been submitted for review by health authorities in the United States, the European Union and Japan. It added at the time that it expected to submit applications in other countries during 2026. The company also said it had filed the trial data for regulatory review in Japan, along with other countries, without specifying a decision date there.

Cosentyx recorded sales of $1.857 billion in the third quarter of 2026, up 9% year over year at constant currencies, according to Novartis results. The company’s report said growth came in most markets, driven by use of the drug in hidradenitis suppurativa and spondyloarthritis. The report added that U.S. sales growth benefited from revenue deduction adjustments recorded in the prior year. These results provide commercial context for the drug before the impact of the new indication is factored in. The information provided did not estimate the effect of the FDA approval on future Cosentyx sales.

Open on chart